Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal of Pharmaceutical and Biomedical Analysis is Scopus-indexed (Q1, CiteScore 6.5), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier B.V..
Checked against the index lists dated .
ISSN 0731-7085Verify ISSN ↗1873-264XVerify ISSN ↗
Publisher: Elsevier B.V.
Cost to publish: About US$3,680 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Spectroscopy | 16 / 81 | 80th | Q1 |
| Clinical Biochemistry | 34 / 124 | 72nd | Q2 |
| Pharmaceutical Science | 53 / 191 | 72nd | Q2 |
| Analytical Chemistry | 50 / 160 | 69th | Q2 |
| Drug Discovery | 51 / 161 | 68th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1983–present, best quartile Q1, CiteScore 6.5.
Journal of Pharmaceutical and Biomedical Analysis is Q1 in Spectroscopy (rank 16 of 81), Q2 in Clinical Biochemistry (rank 34 of 124) and Q2 in Pharmaceutical Science (rank 53 of 191), by CiteScore 2025. It is ranked in 5 subject areas in all.
Journal of Pharmaceutical and Biomedical Analysis is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.5, which places it in quartile Q1 at the 80th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.604, quartile Q2, with an H-index of 160.
The publisher lists an article processing charge of about US$3,680 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Journal of Pharmaceutical and Biomedical Analysis is published by Elsevier B.V. Its print ISSN is 0731-7085 and its online ISSN is 1873-264X.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Journal of Pharmaceutical and Biomedical Analysis has an h-index of 172 and a 2-year mean of 3.67 citations per paper (OpenAlex). Its Scopus CiteScore is 6.5, quartile Q1. On 2-year citations it ranks #23 of 79 Scopus journals in Spectroscopy.
Journal of Pharmaceutical and Biomedical Analysis published 576 papers in 2025; its busiest recent year was 2018 with 720. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2026), authors are most often from China (50.4%), United States (10.2%) and Italy (4.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (0.1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.